FOSTER CITY, CA--(Marketwire - January 05, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced today that it has received from Defiante Farmaceutica S.A,
a company controlled by Sigma-Tau Finanziaria S.p.A, a notice of intention
to nominate four candidates for election to SciClone's seven-person board
at the 2009 annual meeting of SciClone stockholders. The candidates include
two employees of, and a consultant to, Sigma-Tau affiliates.
SciClone also stated that it was aware of the Schedule 13D/A filing with
the Securities and Exchange Commission relating to the nomination notice
that was made on January 2, 2009 by Defiante, Sigma Tau and certain
affiliates which had previously reported aggregate beneficial ownership of
approximately 21.3% of SciClone's common stock.
Dean S. Woodman, Chairman of SciClone's Board of Directors, commented:
"The Board of Directors is evaluating the nomination notice. We are
surprised and disappointed that Sigma-Tau, a valued SciClone investor and
business partner, has chosen to seek control of the Board in this manner.
We believe that the current directors, six of whom are not members of
SciClone's management, and the management of the company have a record of
working to advance the interests of all stockholders, consistent with their
fiduciary duty. We anticipate commenting further on that record in the
future and demonstrating why we believe the contentions about our record
made by the Sigma-Tau parties in their latest SEC filing are inaccurate and
unwarranted. The Board, working closely with management, will continue to
treat the building of long-term stockholder value through SciClone's
business as our priority."
SciClone noted that its stockholders are not being asked to grant any
proxies or take any action at this time with respect to the election of
directors or any other matter that may be submitted for a stockholder vote.
SciClone will announce the scheduled date of the annual meeting after it
has been set.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a global biopharmaceutical
company dedicated to developing and commercializing promising therapies for
life-threatening diseases. SciClone's corporate infrastructure leverages
diverse global resources to finance growth in multiple markets and fund
development of its advanced pipeline of mid- to late-stage product
candidates. SciClone's lead product, ZADAXIN®, is approved for sale in
over 30 countries for the treatment of hepatitis B, hepatitis C, and
certain immune-sensitive cancers. According to SciClone's most recent
publicly issued guidance, sales of ZADAXIN are expected to grow for the
full year 2008 by more than 40% compared to 2007, and are expected to reach
about $49 to $51 million in China alone. SciClone has several products in
clinical development, consisting of thymalfasin for stage IV melanoma,
RP101 for the treatment of pancreatic cancer, and SCV-07 for the treatment
of HCV and oral mucositis; and, awaiting approval in China, DC Bead™ for
the treatment of liver cancer. For additional information, please visit
This press release contains forward-looking statements including our
statement regarding SciClone's expectation for sales of ZADAXIN. You are
urged to consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or other
comparable words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and actual
outcomes may differ materially. These risks and uncertainties include
developments with respect to our products as well as the outcome of the
director nomination notice discussed above. Please also refer to other
risks and uncertainties described in SciClone's filings with the Securities
and Exchange Commission. All forward-looking statements are based on
information currently available to SciClone, and SciClone assumes no
obligation to update any such forward-looking statements.
Important Information/ Solicitation Participants Legend
SciClone Pharmaceuticals, Inc. will file a proxy statement in connection
with its 2009 annual meeting of stockholders and advises its stockholders
to read that proxy statement when it becomes available because it will
contain important information. Stockholders will be able to obtain a free
copy of that proxy statement and other documents (when available) that
SciClone files with the Securities and Exchange Commission at the
Commission's website at www.sec.gov. That proxy statement and these other
documents will also be available free of charge by directing a request to
SciClone Pharmaceuticals, Inc., Attn: Investor Relations, 950 Tower lane,
Suite 900, Foster City, CA 94404, or from SciClone at www.sciclone.com.
SciClone, its directors and named executive officers may be deemed to be
participants in the solicitation of proxies from the SciClone stockholders
in connection with the 2009 annual meeting. Stockholders may obtain
information regarding the names, affiliations and interests of such
individuals in SciClone's proxy statement filed on May 5, 2008 for the 2008
annual meeting of stockholders. To the extent that holdings of SciClone
securities on the part of those individuals have changed since the date of
that proxy statement, those changes have been reflected on Statements of
Changes in Ownership on Forms 3 or 4 filed with the Securities and Exchange
Commission. More current information regarding the interests of the
directors and named executive officers of SciClone will be contained in the
proxy statement referred to in the preceding paragraph.